Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

Autor: Harpreet Singh, Seth Steinberg, Lisa Cordes, Helen Owens, Amy Hankin, Anna Couvillon, Marc R Theoret, Munjid Al-Harthy, Inger I Rosner, Philip M Arlen, Moniquea Williams, Sarah E Lochrin, Cindy H Chau, William Douglas Figg, William Dahut

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)

Background The standard treatment for non-metastatic castration sensitive prostate cancer (nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the potential synergy of immunotherapy and enzalutamide (without ADT) in nm

Externí odkaz: https://doaj.org/article/ef49fdba74d849a0ab9d4e9c35ca2842

Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.

Autor: Marshall CH; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Marylands., Chen Y; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands., Kuo C; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands., Cullen J; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Marylands., Jiang J; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Marylands., Rosner I; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands., Markowski M; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Marylands., McLeod DG; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, Marylands., Trock BJ; Department of Urology, Johns Hopkins School of Medicine, Baltimore, Marylands., Eisenberger MA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Marylands.

Publikováno v: The Journal of urology [J Urol] 2021 Sep; Vol. 206 (3), pp. 623-629. Date of Electronic Publication: 2021 May 18.

Characterization of unique PMEPA1 gene splice variants (isoforms d and e ) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer.

Autor: Sharad S; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; Henry Jackson Foundation for the Advancement of Military Medicine (HJF), Bethesda, Maryland, 20817, USA.; These authors contributed equally to this work., Dillman AA; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; Henry Jackson Foundation for the Advancement of Military Medicine (HJF), Bethesda, Maryland, 20817, USA., Sztupinszki ZM; Danish Cancer Society Research Center, Copenhagen, 2100, Denmark., Szallasi Z; Danish Cancer Society Research Center, Copenhagen, 2100, Denmark.; Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA.; SE-NAP Brain Metastasis Research Group, 2nd Department of Pathology, Semmelweis University, Budapest, 1085, Hungary., Rosner I; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; Urology Service, Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA., Cullen J; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; Henry Jackson Foundation for the Advancement of Military Medicine (HJF), Bethesda, Maryland, 20817, USA., Srivastava S; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA., Srinivasan A; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; Henry Jackson Foundation for the Advancement of Military Medicine (HJF), Bethesda, Maryland, 20817, USA., Li H; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA.; These authors contributed equally to this work.

Publikováno v: Oncotarget [Oncotarget] 2020 Jan 28; Vol. 11 (4), pp. 362-377. Date of Electronic Publication: 2020 Jan 28 (Print Publication: 2020).

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.

Autor: Madan RA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Karzai FH; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Ning YM; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Adesunloye BA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Huang X; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Harold N; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Couvillon A; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Chun G; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Cordes L; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Sissung T; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Beedie SL; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Dawson NA; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C., USA., Theoret MR; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., McLeod DG; Center for Prostate Disease Research, Walter Reed National Military Medical Center, Bethesda, MD, USA., Rosner I; Center for Prostate Disease Research, Walter Reed National Military Medical Center, Bethesda, MD, USA., Trepel JB; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Lee MJ; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Tomita Y; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Lee S; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Chen C; Radiology and Imaging Sciences, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Steinberg SM; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Arlen PM; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Gulley JL; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Figg WD; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. wdfigg@helix.nih.gov., Dahut WL; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Publikováno v: BJU international [BJU Int] 2016 Oct; Vol. 118 (4), pp. 590-7. Date of Electronic Publication: 2016 Feb 19.

The clinical implications of the genetics of renal cell carcinoma.

Autor: Rosner I; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Bratslavsky G, Pinto PA, Linehan WM

Publikováno v: Urologic oncology [Urol Oncol] 2009 Mar-Apr; Vol. 27 (2), pp. 131-6.